1,742
Participants
Start Date
October 31, 2007
Primary Completion Date
May 31, 2009
Study Completion Date
May 31, 2009
Naltrexone SR 16 mg/Bupropion SR 360 mg /day
Naltrexone SR 32 mg/Bupropion SR 360 mg /day
Placebo
Ancillary therapy
Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
Health Trends Research, LLC, Baltimore
Wake Research Associates, LLC, Raleigh
Center for Nutrition and Preventive Medicine, Charlotte
Georgia Clinical Research, Atlanta
CSRA Partners in Health, Inc, Augusta
University Clinical Research, Pembroke Pines
Miami Research Associates, Miami
Radiant Research, Birmingham
SelfCenter, PC, Fairhope
Internal Medicine Associates of Cordova, Cordova
Jackson Clinic, PA, Jackson
Central Kentucky Research Associates, Inc., Lexington
Central Ohio Nutrition Center, Inc., Columbus
Rapid Medical Research, Inc., Cleveland
Welborn Clinic, Evansville
Radiant Research, Chicago
Radiant Research Kansas City, Overland Park
Medical Research Institute, Slidell
Pennington Biomedical Research Center, Baton Rouge
Lynn Health Science Institute, Oklahoma City
Radiant Research, Dallas
Baylor Endocrine Center, Dallas
Radiant Research, San Antonio
Oakwell Clinical Research, San Antonio
Covance Clinical Research Unit Austin, Austin
Radiant Research, Phoenix Southeast, Chandler
Center for Nutrition and Metabolic Disorders, Reno
Scripps Clinic Del Mar, San Diego
VA San Diego Healthcare System, San Diego
Advanced Clinical Research Institute, Anaheim
Advance Clinical Research Institute, Orange
East-West Medical Research Institute, Honolulu
Summit Research Network (Oregon), Inc., Portland
FutureCare Studies, Springfield
Lead Sponsor
Orexigen Therapeutics, Inc
INDUSTRY